Importantly, Retatrutide's unique triple receptor agonismtargeting GLP-1, GIP, and glucagon receptorsappears well-tolerated, with adverse events largely consistent with known effects from the broader GLP-1 class, primarily mild gastrointestinal symptoms such as nausea, decreased appetite, and occasional diarrhea, typically resolving within a few weeks of initiation
Providers must evaluate each patient individually
In the STEP and SURMOUNT trials for semaglutide and tirzepatide respectively, weight loss curves generally began to flatten between weeks 36 and 60, reflecting the physiological set point adaptation that occurs as appetite suppression becomes partially offset by metabolic adaptation
If you struggle with autoimmunity or gut health issues, its important to work with a practitioner to help guide your healing journey
Without insurance, Zepbound can be expensive